Inhibiting hyperactive or synthetically lethal DDR components (e.g., PARP, ATM, ATR, DNA-PK, Wee1) in cancer cells can impair the repair of radiation-induced DNA damage, particularly double-strand breaks (DSB), thereby achieving targeted radiosensitization (7). Here, PARP1 is linked to cancer.